Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Moligand™, 10mM in DMSO Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 18 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
In vitro
Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function.
In vivo
Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington\'s disease.
Cell Data
cell lines:
Concentrations:Dissolved in DMSO, final concentrations ~7.5 μM
Incubation Time:1, 2, 3 and 4 days
Powder Purity:≥99%
| ALogP | 1.9 |
|---|
| Isomeric SMILES | C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO |
|---|---|
| WGK Germany | 3 |
| PubChem CID | 5311 |
| Molecular Weight | 264.32 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Solubility | Solubility (25°C) In vitro DMSO: 100 mg/mL (85.2 mM); Ethanol: 100 mg/mL (85.2 mM); Water: Insoluble; |
|---|---|
| Melt Point(°C) | 155 °C |
| 1. Lei Hou, Yunchang Zhang, Ying Huang, Zhen Fang, Guangze Sang, Tianheng Chen, Zhiqiang Ma, Feng Yang. (2022) Coupling Chlorin-Based Photosensitizers and Histone Deacetylase Inhibitors for Photodynamic Chemotherapy. MOLECULAR PHARMACEUTICS, [PMID:35758904] [10.1021/acs.molpharmaceut.2c00170] |
| 2. Jia Man, Xiaojie Wang, Jianyong Li, Xiaoyang Cui, Zesheng Hua, Jianfeng Li, Zebing Mao, Shanguo Zhang. (2022) Intravenous Calcium Alginate Microspheres as Drug Delivery Vehicles in Acute Kidney Injury Treatment. Micromachines, 13 (4): (538). [PMID:35457843] [10.3390/mi13040538] |
| 3. Yingjie Yu, Bingkai Wang, Miao Sun, Yunchang Zhang, Lei Hou, Sizhen Wang, Tianheng Chen, Feng Yang, Zhiqiang Ma. (2022) Lysosomal activable Vorinostat carrier-prodrug self-assembling with BPQDs enables photothermal oncotherapy to reverse tumor thermotolerance and metastasis. INTERNATIONAL JOURNAL OF PHARMACEUTICS, [PMID:35202725] [10.1016/j.ijpharm.2022.121580] |
| 4. Miao Jiefei, Meng Chi, Wu Hongmei, Shan Wenpei, Wang Haoran, Ling Changchun, Zhang Jinlin, Yang Tao. (2021) Novel Hybrid CHC from β-carboline and N-Hydroxyacrylamide Overcomes Drug-Resistant Hepatocellular Carcinoma by Promoting Apoptosis, DNA Damage, and Cell Cycle Arrest. Frontiers in Pharmacology, [PMID:33536926] [10.3389/fphar.2020.626065] |
| 5. Shanguo Zhang, Xiaojie Wang, Jia Man, Jianyong Li, Xiaoyang Cui, Chuanwei Zhang, Weichen Shi, Donghai Li, Song Zhang, Jianfeng Li. (2020) Histone Deacetylase Inhibitor-loaded Calcium Alginate Microspheres for Acute Kidney Injury Treatment. ACS Applied Bio Materials, [PMID:35021777] [10.1021/acsabm.0c00874] |
| 6. Qian Zhu, Lixin Jia, Zhongfei Gao, Chunming Wang, Haoyang Jiang, Junfeng Zhang, Lei Dong. (2014) A Tumor Environment Responsive Doxorubicin-Loaded Nanoparticle for Targeted Cancer Therapy. MOLECULAR PHARMACEUTICS, [PMID:24735448] [10.1021/mp4007776] |
| 7. Weiwei Jiang, Yuwei Cheng, Lei Hou, Ying Huang, Sizhen Wang, Yunchang Zhang, Tao Jiang, Feng Yang, Zhiqiang Ma. (2024) A dual-prodrug nanogel combining Vorinostat and Pyropheophorbide a for a high efficient photochemotherapy. INTERNATIONAL JOURNAL OF PHARMACEUTICS, [PMID:38977163] [10.1016/j.ijpharm.2024.124422] |
| 8. Lu Hui, Fu Wenying, Xia Yiqun, Yan Ying, Shu Chongchong, Chen Yinghua, Xu Chenxin, Zheng Peisen, Shen Xin, Cui Ri, Zou Peng, Ni Daoyong. (2025) Panobinostat potentiates adagrasib-induced cell death by triggering autophagy in human non-small cell lung cancer. Cell Death Discovery, 11 (1): (1-16). [PMID:40750601] [10.1038/s41420-025-02657-9] |
| 9. Penghui Du, Wen Liu, Qiang Zhang, Peng Zhang, Chen He, Quan Shi, Ching-Hua Huang, Junjian Wang. (2023) Transformation of dissolved organic matter during UV/peracetic acid treatment. WATER RESEARCH, [PMID:36738558] [10.1016/j.watres.2023.119676] |
| 10. Yaowei Guo, Jin Liu, Qinglin Tang, Cuicui Li, Yanying Zhang, Yao Wang, Yanxin Wang, Yupeng Bi, Christopher D. Snow, Matt J. Kipper, Laurence A. Belfiore, Jianguo Tang. (2022) Lanthanide (Eu3+/Tb3+)-Loaded γ-Cyclodextrin Nano-Aggregates for Smart Sensing of the Anticancer Drug Irinotecan. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23 (12): (6597). [PMID:35743042] [10.3390/ijms23126597] |
| 11. Yue Wei, Si Wu, Zhenqi Liu, Jingsheng Niu, Ya Zhou, Jinsong Ren, Xiaogang Qu. (2022) Tumor associated macrophages reprogrammed by targeted bifunctional bioorthogonal nanozymes for enhanced tumor immunotherapy. Materials Today, [PMID:] [10.1016/j.mattod.2022.01.024] |
| 12. Rui Li, Li Xie, Lei Li, Xiaojiao Chen, Tong Yao, Yuanxin Tian, Qingping Li, Kai Wang, Chenyang Huang, Cui Li, Yifan Li, Hongwei Zhou, Neil Kaplowitz, Yong Jiang, Peng Chen. (2021) The gut microbial metabolite, 3,4-dihydroxyphenylpropionic acid, alleviates hepatic ischemia/reperfusion injury via mitigation of macrophage pro-inflammatory activity in mice. Acta Pharmaceutica Sinica B, [PMID:35127379] [10.1016/j.apsb.2021.05.029] |
| 13. Pisano S., Wang X., Garcia-Parra J., Gazze A., Edwards K., Feltracco V., Hu Y., He L., Gonzalez D., Francis L. W., Conlan R. S., Li C.. (2020) Nanomicelles potentiate histone deacetylase inhibitor efficacy in vitro. Cancer Nanotechnology, 11 (1): (1-17). [PMID:] [10.1186/s12645-020-00070-8] |
| 14. Xie Qiu-shi, Zhang Jia-xin, Liu Ming, Liu Pei-hua, Wang Zhong-jian, Zhu Liang, Jiang Ling, Jin Meng-meng, Liu Xiao-nan, Liu Li, Liu Xiao-dong. (2020) Short-chain fatty acids exert opposite effects on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine. ACTA PHARMACOLOGICA SINICA, 42 (3): (470-481). [PMID:32555444] [10.1038/s41401-020-0402-x] |
| 15. Zhihong Yao, Shishi Li, Zifei Qin, Xiaodan Hong, Yi Dai, Baojian Wu, Wencai Ye, Frank J. Gonzalez, Xinsheng Yao. (2017) Characterization of human UDP-glucuronosyltransferases responsible for glucuronidation and inhibition of norbakuchinic acid, a primary metabolite of hepatotoxicity and nephrotoxicity component bakuchiol in Psoralea corylifolia L.. RSC Advances, 7 (83): (52661-52671). [PMID:] [10.1039/C7RA10376J] |
| 16. Dong Shanshan, Li Mu, Chen Yinguang. (2017) Inherent humic substance promotes microbial denitrification of landfill leachate via shifting bacterial community, improving enzyme activity and up-regulating gene. Scientific Reports, 7 (1): (1-10). [PMID:28939832] [10.1038/s41598-017-12565-3] |
| 17. Xiao-Li Zheng, Zhi-Di Li, Kai-Zhi Luo, Yang-Ling Li, Ye-Han Liu, Shu-Ying Shen, Fei-Yan Shen, Wan-Yan Li, Guo-Qing Chen, Chong Zhang, Ling-Hui Zeng. (2024) POLR2J expression promotes glioblastoma malignancy by regulating oxidative stress and the STAT3 signaling pathway. American Journal of Cancer Research, [PMID:38859843] [10.62347/JEWM7691] |
| 18. Yanhong Guo, Shuhao Xu, Xue Guo, Jing Xu, Zhenyu Li, Ying Wang, Zhenhao Li, Zheyong Xue. (2026) Synergistic effects of exogenous inducers on ganoderic acid accumulation in Ganoderma lucidum: optimization and transcriptomic analysis. Medicinal Plant Biology, 5 (1): [PMID:] [10.48130/mpb-0025-0039] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →